OTLK
Outlook Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.49
+0.98%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.49
From 52W high−80.04%
Volume2.61M
Market cap$120.02M
P/E (TTM)—
P/S (TTM)−103.2x
Div yield—
Key dataOct 19, 2026
Open
$0.49
From 52W high
−80.04%
Volume
2.61M
Market cap
$120.02M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.0x
P/E (TTM)
—
RSI (14)
34.5
MomentumView details →
1D Return
+0.98%
YTD Return
−68.56%
SummaryUpdated Jun 1, 2026
Outlook Therapeutics, Inc. (NASDAQ:OTLK) is a late-stage biopharmaceutical company founded in 2010 and headquartered in Iselin, New Jersey. Originally incorporated as Oncobiologics, Inc., the company rebranded to Outlook Therapeutics in November 2018 to reflect its strategic pivot toward ophthalmology. The company went public in 2016 and has evolved from a broader oncology focus to specialize exclusively in developing monoclonal antibody treatments for eye diseases, particularly retinal disorders that can cause blindness.
Similar companies
Latest newsMore news →
Outlook Therapeutics, Inc. named Greg DiPasquale chief commercial officer to lead U.S. commercialization of LYTENAVA.10d agoOutlook Therapeutics, Inc. received a NASDAQ notice dated September 25, 2026 that it no longer complies with the minimum bid price requirement under Rule 5550(a)(2), with a compliance deadline of March 24, 2027.19d ago